Angiogenesis in non-small cell lung cancer: A new target for therapy

American Journal of Respiratory Medicine

Volumn 1, Issue 5, 2002, Pages 325-338

  Kim, Tracy E ^a   Murren, John R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AE 941; ALPHA2A INTERFERON; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BB 2561; BEVACIZUMAB; CARBOPLATIN; CELL ADHESION MOLECULE; CISPLATIN; CYTOSTATIC AGENT; ENDOSTATIN; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; PACLITAXEL; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PRINOMASTAT; REBIMASTAT; SQUALAMINE; TANOMASTAT; THALIDOMIDE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CYTOSTASIS; DRUG ACTIVITY; DRUG TARGETING; EVIDENCE BASED MEDICINE; HUMAN; HYPERBILIRUBINEMIA; IMAGE ANALYSIS; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA; VALIDATION PROCESS; VASCULAR ENDOTHELIUM;

EID: 0042858124     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256626     Document Type: Article

References (158)

1. Cancer facts and figures [online]. Available from URL: http://www.cancer.org [Accessed 2002 Aug 30]
2. Ginsberg R, Vokes E, Rosenzweig K. Non-small cell lung cancer. In: DeVita Jr V, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 925-82
3. Sherer D, Abulafia O. Angiogenesis during implantation, and placental and early embryonic development. Placenta 2001; 22: 1-13
4. Folkman J. Angiogenesis in female reproductive organs. In: Alexander N, d'Arcangues C, editors. Steroid hormones and uterine bleeding. Washington, DC: AAAS Press, 1992: 143-58
5. Nissen N, DiPietro L. Angiogenic mediators in healing wounds. In: Rubanyi G, editor. Angiogenesis in health and disease: basic mechanisms and clinical applications. New York: Marcel Dekker, Inc., 2000: 417-27
6. Szekanecz Z, Koch A. Angiogenesis in rheumatoid arthritis. In: Rubanyi G, editor. Angiogenesis in health and disease: basic mechanisms and clinical applications. New York: Marcel Dekker, Inc., 2000: 429-50
7. Nickoloff B, Mitra R, Varani J, et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820-8
8. Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001; 189: 323-33
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64
11. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continous labelling studies. Br J Cancer 1984; 49: 405-13
12. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996; 2: 167-8
13. Rak J, Filmus J, Kerbel R. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenic progression' hypothesis. Eur J Cancer 1996; 32A: 2438-50
14. Brooks P. Role of integrins in angiogenesis. Eur J Cancer 1996; 32A: 2423-9
15. Brooks P, Clark R, Cheresh D. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71
16. 5 integrin antagonist EMD 121974 [abstract 110]. Proc Am Soc Clin Oncol 2002; 21: 28a
17. Koch A, Halloran M, Haskell C, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376: 517-9
18. Maier J, Delia D, Thorpe P, et al. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 1997; 8: 238-44
19. Cox G, Steward W, O'Byrne K. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 1999; 54: 169-79
20. Glass W, Radnik R, Garoni J, et al. Urokinase-dependent adhesion loss and shape change afer cyclic adenosine monophosphate elevation in cultured rat mesangial cells. J Clin Invest 1988; 82: 1992-2000
21. Andreasen P, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22
22. Nagayama M, Sato A, Hayakawa H, et al. Plasminogen activators and their inhibitors in non-small cell lung cancer: low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 1994; 73: 1398-405
23. Robert C, Bolen I, Gazzeri S, et al. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clin Cancer Res 1999; 5: 2094-102
24. Reuning U, Magdolen V, Wilhelm O, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998; 13: 893-906
25. Pedersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor and type-1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-5
26. Muchlenweg B, Sperl S, Madolen V, et al. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin Biol Ther 2001; 1: 683-91
27. Nelson A, Fingleton B, Rothenberg M, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49
28. Hidalgo M, Eckhardt S. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-93
29. Bolon I, Devouasoux M, Moro R, et al. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol 1997; 150: 1619-29
30. Brown P, Bloxidge R, Stuart N, et al. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574-8
31. Nawrocki B, Polette M, Marchand V, et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 1997; 72: 556-64
32. Tokuraku M, Sato H, Murakami S, et al. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995; 64: 355-9
33. Folkman J, Merler E, Abernathy C, et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88
34. Shing Y, Folkman J, Sullivan R, et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984; 223: 1296-9
35. Esch F, Ueno N, Baird A, et al. Primary structure of bovine brain acidic fibroblast growth factor. Biochem Biophys Res Commun 1985; 133: 554-62
36. Fett J, Strydom D, Lobb R, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985; 24: 5480-6
37. Schreiber A, Winkler M, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250-3
38. Roberts A, Sporn M, Assoian R, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986; 83: 4167-71
39. Frater-Schroder M, Risau W, Hallmann R, et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A 1987; 84: 5277-88
40. Senger D, Galli S, Dvorak A, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5
41. Leung D, Cachianes G, Kuang W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9
42. Bussolino F, Wang J, Defilippi P, et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471-3
43. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338: 557-62
44. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991; 88: 9267-71
45. Koch A, Polverini P, Kunkel S, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-801
46. Fang W, Hartmann N, Chow D, et al. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem 1992; 267: 25889-97
47. Rosen E, Grant D, Kleinman H, et al. Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp Soc Exp Biol 1993; 47: 227-34
48. Jackson D, Volpert O, Bouck N, et al. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 1994; 266: 1581-4
49. Suri C, Jones P, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80
50. Kozian D, Ziche M, Augustin H. The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest 1997; 76: 267-76
51. Sierra-Honigmann M, Nath A, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683-6
52. Dvorak H, Brown L, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39
53. Nor J, Christensen J, Mooney D, et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999; 154: 375-84
54. Unemori E, Ferrara N, Bauer E, et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992; 153: 557-62
55. Mandriota S, Seghezzi G, Vassalli J, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995; 270: 9709-16
56. Pepper M, Ferrera N, Orci L, et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor type 1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902-6
57. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5
58. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22
59. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-80
60. Kieser A, Welch H, Brandner G, et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-9
61. Senger D, Van de Water L, Brown L, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12: 303-24
62. Yuan A, Yu C, Kuo S, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001; 19: 432-41
63. Bork P, Downing K, Kieffer B, et al. Structure and distribution of modules in extracellular proteins. Q Rev Biophysics 1996; 29: 119-67
64. de Vries C, Escobedo J, Ueno H, et al. The fms-like tyrosine, kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91
65. Terman B, Dougher-Vermazen M, Carrion M, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-86
66. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6
67. Ezekowitz R, Mulliken J, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-63
68. The Angiogenesis Foundation [online]. Available from URL: http://www.angio.org [Accessed 2002 Aug 30]
69. Sidky Y, Borden E. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5155-61
70. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104: 689-96
71. Docherty A, Lyons A, Smith B, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318: 66-8
72. Stetler-Stevenson W, Krutzsch H, Liotta L. Tissue inhibitor of metalloproteinase (TIMP-2). J Biol Chem 1989; 264: 17374-8
73. Apte S, Mattei M, Olsen B. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 1994; 19: 86-90
74. Olson T, Hirohata S, Ye J, et al. Cloning of the human tissue inhibitor of metalloproteinase-4 gene (TIMP4) and localization of the TIMP4 and TIMP4 genes to human chromosome 3p25 and mouse chromosome 6, respectively. Genomics 1998; 51: 148-51
75. Sato Y, Abe M, Takaki R. Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 1990; 172: 595-600
76. Iruela-Arispe M. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A 1991; 88: 5026-30
77. Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991; 129: 896-900
78. O'Reilly M, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28
79. Voest E, Kenyon B, O'Reilly M, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-6
80. O'Reilly M, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85
81. Maisonpierre P, Suri C, Jones P, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60
82. Pike S, Yao L, Jones K, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998; 188: 2349-56
83. Vazquez F, Hastings G, Ortega M, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999; 274: 23349-57
84. Dawson D, Volpert O, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-8
85. Fortier A, Nelson B, Grella D, et al. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999; 91: 1635-40
86. O'Reilly M, Pirie-Shepherd S, Lane W, et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-8
87. Moses M, Wiederschain D, Wu I, et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 1999; 96: 2645-50
88. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A 1999; 96: 14888-593
89. Zhai Y, Ni J, Jiang G, et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 1999; 13: 181-9
90. Kamphaus G, Colorado P, Panka D, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275: 1209-15
91. Liu N, Lapcevich R, Underhill C, et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 2001; 61: 1022-8
92. O'Reilly M, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92
93. Volm M, Mattern J, Koomagi R. Angiostatin expression in non-small cell lung cancer. Clin Cancer Res 2000; 6 (8): 3236-40
94. DeMoraes E, Fogler W, Grant D, et al. Recombinant human angiostatin: a phase I clinical trial assessing safety, pharmacokinetics and pharmacodynamics [abstract no. 10]. Proc Am Soc Clin Oncol 2001; 20: 3a
95. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7
96. New drugs for cancer therapy. Proceedings of the 11th NCI-EORTC-AACR Symposium; 2000 Nov 9; Amsterdam
97. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990; 348: 555-7
98. Milkowski D, Weiss R. TNP-470: preclinical and clinical development. In: Voest E, D'Amore P, editors. Tumor angiogenesis and microcirculation. New York: Marcel Dekker, Inc., 2001: 431-47
99. Satoh H, Ishikawa H, Fujimoto M, et al. Combined effects of TNP-470 and taxol in human non-small cell lung cancer cell lines. Anticancer Res 1998; 18: 1027-30
100. Herbst R, Tran H, Madden T, et al. Phase I study of the angiogenesis inhibitor TNP-470 in combination of paclitaxel in patients with solid tumors [abstract no. 707]. Proc Am Soc Clin Oncol 2000; 19: 182a
101. Tran H, Blumenschein JGL, Madden T, et al. Phase I study of the angiogenesis inhibitor TNP-470 in combination with paclitaxel and carboplatin in patients with solid tumors [abstract no. 394]. Proc Am Soc Clin Oncol 2001; 20: 99a
102. Schultz R, Silberman S, Persky B, et al. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48: 5539-45
103. Alvarez O, Carmichael D, DeClerck Y. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990; 82: 589-95
104. Blavier L, Henriet P, Imren S, et al. Tissue inhibitors of matrix metalloproteinases in cancer. Ann N Y Acad Sci 1999; 878: 108-19
105. Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998; 16: 2150-6
106. Shepherd F, Giaccone G, Debruyne C, et al. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer following response to first-line chemotherapy: an NCIC-CTG and EORTC study [abstract no. 11]. Proc Am Soc Clin Oncol 2001; 20: 4a
107. Anderson I, Supko J, Eder J. Pilot pharmacokinetic study of marimastat in combination with carboplatin/paclitaxel in patients with metastatic or locally advanced inoperable non-small cell lung cancer [abstract 719]. Proc Am Soc Clin Oncol 1999; 18: 187a
108. Gingras D, Renaud A, Mousseau N, et al. Matrix proteinase inhibition by AE-941, a multifunctional anti-angiogenic compound. Anticancer Res 2001; 21: 145-55
109. Falardeau P, Champagne P, Poyet P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001; 28: 620-5
110. Hurwitz H, Humphrey J, Williams K, et al. A phase I trial of BMS-275291: a novel, non-hydroxamate, sheddase-sparing matrix metalloproteinase inhibitor with no dose-limiting arthritis [abstract no. 387]. Proc Am Soc Clin Oncol 2001; 20: 98a
111. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC) [abstract no. 1226]. Proc Am Soc Clin Oncol 2001; 20: 307a
112. Rowinsky E, Humphrey R, Hammond L, et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000; 18: 178-86
113. Levitt N, Eskens F, O'Byrne K, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001; 7: 1912-22
114. Asano M, Yukita A, Suzuki H. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 1999; 90: 93-100
115. Presta L, Chen H, O'Connor S, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9
116. Gordon M, Margolin M, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50
117. DeVore R, Fehrenbacher L, Herbst R, et al. A randomized phase II trial comparing Rhumab VEGF plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC [abstract no. 1896]. Proc Am Soc Clin Oncol 2000; 19: 485a
118. Rosen L. VEGF inhibition: semaxanib (SU5416) - from concept to clinical use. Proceedings of the Third European Congress on Perspectives in Colorectal Cancer; 2001; Dublin, Ireland
119. Laird A, Vajkoczy P, Shawver L, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152-60
120. Ning S, Laird D, Cherrington J, et al. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002; 157: 45-51
121. Rosen L, Rosen P, Kabbinavar F, et al. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibibitor in patients with advanced malignancies [abstract no. 383]. Proc Am Soc Clin Oncol 2001; 20: 97a
122. Mendel DB, Laird AD, Xin X, et al. Development of a preclinical pharmacokinetic/pharmacodynamic relationship for the angiogenesis inhibitor SU11248, a selective inhibitor of VEGF and PDGF receptor tyrosine kinases in clinical development [abstract 94]. Proc Am Soc Clin Oncol 2002; 21: 24a
123. Sugen [online]. Available from URL: http:\\www.sugen.com [Accessed 2002 Aug 30]
124. D'Amato R. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5
125. Merchant J, Hammes L, Larson M, et al. Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer [abstract no. 2130]. Proc Am Soc Clin Oncol 2000; 19: 541a
126. Marriott J, Muller G, Stirling D, et al. Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 2001; 1: 675-82
127. Schiller J, Bittner G. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. Clin Cancer Res 1999; 5: 4287-94
128. Williams J, Weitman S, Gonzalez C, et al. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res 2001; 7: 724-33
129. Kalidas M, Hammond L, Patnaik A, et al. A phase I and pharmacokinetic study of the angiogenesis inhibitor, squalamine lactate (MSI-1256F) [Abstract no. 698]. Proc Am Soc Clin Oncol 2000; 19: 180a
130. Schiller J, Hammond L, Carbone D, et al. Phase 2A trial of squalamine for treatment of advanced non-small cell lung cancer [abstract 1353]. Proc Am Soc Clin Oncol 2001; 20: 339a
131. Kohn E, Felder C, Jacobs W, et al. Structure function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 1994; 54: 935-42
132. Kohn E, Alessandro R, Spoonster J, et al. Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci U S A 1995; 92: 1307-11
133. Kohn E, Reed E, Sarosy G, et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996; 56: 569-73
134. Kohn E, Reed E, Sarosy G, et al. A phase 1 trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res 2001; 7: 1600-9
135. Weidner N, Semple J, Welch W, et al. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8
136. Gasparini G, Harris A. Prognostic significance of tumor vascularity. In: Teicher B, editor. Antiangiogenic agents in cancer therapy. Totowa: Humana Press, 1999: 317-40
137. Vermeulen P, Gasparini G, Fox S, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474-84
138. Macchiarini P, Fontanini G, Hardin J, et al. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992; 340: 145-6
139. Pastorino U, Andreola S, Taglibue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-65
140. Giatromanolaki A, Koukourakis A, O'Byrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996; 179: 80-8
141. Apolinario R, van der Valk P, de Jong J, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997; 15: 2456-66
142. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-6
143. Angeletti C, Lucchi M, Fontanini G, et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 1996; 78: 409-15
144. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7: 3410-5
145. Fox S, Leek R, Weekes M. Quantification and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chaulkley count and computer image analysis. J Pathol 1995; 177: 275-83
146. Anderson H, Price P, Blomley M, et al. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 2001; 85: 1085-93
147. Padhani A, Neeman M. Challenges for imaging angiogenesis. Br J Radiol 2001; 74: 886-90
148. Wild R, Ramakrishnan S, Sedgewick J, et al. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000; 59: 368-76
149. Guo L, Burke P, Lo S, et al. Quantitative analysis of angiogenesis using confocal lase scanning microscopy. Angiogenesis 2001; 4: 187-91
150. Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999; 5: 149-53
151. Nguyen M, Watanabe H, Budson A, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-61
152. Takigawa N, Segawa Y, Fujimoto N, et al. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 1998; 18: 1251-4
153. Ueno K, Inoue Y, Kawaguchi T, et al. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001; 31: 213-9
154. Poon R, Fan S, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25
155. Stadler W, Ratain M. Development of target-based antineoplastic agents. Invest New Drugs 2000; 18: 7-16
156. Millar A, Brown P, Moore J, et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998; 45: 21-6
157. Amery W, Dony J. A clinical trial design avoiding undue placebo treatment. J Clin Pharmacol 1975; 15: 674-9
158. Kopec J, Abramhamowicz M, Esdaile J. Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol 1993; 46: 959-71